These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9425528)

  • 21. Visual dysfunction in Parkinson's disease.
    Rodnitzky RL
    Clin Neurosci; 1998; 5(2):102-6. PubMed ID: 10785835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How many pathways determine the speed of grating detection?
    Mitov D; Totev T
    Vision Res; 2005 Mar; 45(7):821-5. PubMed ID: 15644222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease.
    Shin HW; Kang SY; Sohn YH
    Mov Disord; 2005 Dec; 20(12):1640-3. PubMed ID: 16092109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levodopa-induced alterations in speech rate in advanced Parkinson's disease.
    De Letter M; Santens P; De Bodt M; Boon P; Van Borsel J
    Acta Neurol Belg; 2006 Mar; 106(1):19-22. PubMed ID: 16776432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated vernier acuity thresholds in glaucoma.
    McKendrick AM; Johnson CA; Anderson AJ; Fortune B
    Invest Ophthalmol Vis Sci; 2002 May; 43(5):1393-9. PubMed ID: 11980852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson's disease.
    Vaillancourt DE; Prodoehl J; Verhagen Metman L; Bakay RA; Corcos DM
    Brain; 2004 Mar; 127(Pt 3):491-504. PubMed ID: 14662520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Relationship between weight loss and dysphagia in patients with Parkinson's disease].
    Nozaki S; Saito T; Matsumura T; Miyai I; Kang J
    Rinsho Shinkeigaku; 1999 Oct; 39(10):1010-4. PubMed ID: 10655760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Three-dimensional gait biomechanics in Parkinson's disease: evidence for a centrally mediated amplitude regulation disorder.
    Morris M; Iansek R; McGinley J; Matyas T; Huxham F
    Mov Disord; 2005 Jan; 20(1):40-50. PubMed ID: 15390033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease.
    Matsui H; Udaka F; Tamura A; Oda M; Kubori T; Nishinaka K; Kameyama M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):36-40. PubMed ID: 16449759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 300-Hz subthalamic oscillations in Parkinson's disease.
    Foffani G; Priori A; Egidi M; Rampini P; Tamma F; Caputo E; Moxon KA; Cerutti S; Barbieri S
    Brain; 2003 Oct; 126(Pt 10):2153-63. PubMed ID: 12937087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severity staging by early features of age-related maculopathy exhibits weak relationships with functional deficits on SWS grating acuity.
    Beirne RO; Hogg RE; Stevenson MR; Zlatkova MB; Chakravarthy U; Anderson RS
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4624-31. PubMed ID: 17003460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gait analysis in patients with Parkinson's disease and motor fluctuations: influence of levodopa and comparison with other measures of motor function.
    O'Sullivan JD; Said CM; Dillon LC; Hoffman M; Hughes AJ
    Mov Disord; 1998 Nov; 13(6):900-6. PubMed ID: 9827613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
    Shohamy D; Myers CE; Grossman S; Sage J; Gluck MA
    Behav Brain Res; 2005 Jan; 156(2):191-9. PubMed ID: 15582105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Visual acuity for optotypes made visible by relative motion.
    Regan D; Hong XH
    Optom Vis Sci; 1990 Jan; 67(1):49-55. PubMed ID: 2308752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
    Stacy M; Bowron A; Guttman M; Hauser R; Hughes K; Larsen JP; LeWitt P; Oertel W; Quinn N; Sethi K; Stocchi F
    Mov Disord; 2005 Jun; 20(6):726-33. PubMed ID: 15719426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dysfunction of the magnocellular pathway in Alzheimer's disease].
    Jacob B; Hache JC; Pasquier F
    Rev Neurol (Paris); 2002 May; 158(5 Pt 1):555-64. PubMed ID: 12072823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of basal ganglia on upper limb locomotor synergies. Evidence from deep brain stimulation and L-DOPA treatment in Parkinson's disease.
    Crenna P; Carpinella I; Lopiano L; Marzegan A; Rabuffetti M; Rizzone M; Lanotte M; Ferrarin M
    Brain; 2008 Dec; 131(Pt 12):3410-20. PubMed ID: 18952669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Two cases of Parkinson's disease in which visual hallucinations disappeared after cataract surgery].
    Matsui H; Udaka F; Oda M; Kubori T; Nishinaka K; Kameyama M
    No To Shinkei; 2004 Apr; 56(4):351-4. PubMed ID: 15237728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.